DS 1647

Drug Profile

DS 1647

Alternative Names: DS-1647; G47 delta oncolytic virus therapy; G47 delta oncolytic virus therapy - Daiichi Sankyo/University of Tokyo; G47 Δ oncolytic virus therapy; G47-delta; G47Δ oncolytic virus therapy - Daiichi Sankyo/University of Tokyo

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company; University of Tokyo
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Gene transference; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Prostate cancer

Most Recent Events

  • 11 Jul 2017 DS 1647 receives Orphan Drug status for Glioma in USA
  • 02 Feb 2017 Daiichi Sankyo and ActiVec agree to co-develop DS 1647 before February 2017 (Daiichi Sankyo pipeline, February 2017)
  • 06 May 2016 Adverse events data from a phase I trial in Prostate cancer presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top